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The  second  meeting  of  the  Afriﬂu  conferences  took  place  in Cape  Town,  South  Africa,  with over  60 par-
ticipants  from  15  countries  in Africa  and  also  outside  the continent.  Signiﬁcant  progress  in surveillance
has  been  made  in  better  understanding  the  illness  burden  of  inﬂuenza  on  the  continent,  which  limited
evidence  suggests  is greater  than  that  in  the  developed  world.  In  southern  Africa  HIV  and  TB  coinfections
play  a major  role  in  increasing  hospitalisation  and mortality,  while  elsewhere  in Africa other  cofactors
still  need  to be determined.
There  is  currently  no indigenous  vaccine  production  in  sub-Saharan  Africa  and  only  one  facility,  based
in  South  Africa,  capable  of ﬁlling  imported  bulk.  Innovative  vaccine  strategies  will need  to  be explored,
such  as  maternal  immunisation,  and  also  the  possibility  of other  inﬂuenza  vaccine  options,  such  as  live
attenuated  inﬂuenza  vaccine  for young  children.  Sustained  indigenous  vaccine  production  is  essential
for  the  continent  to  have  vaccine  security  in the event  of  a pandemic  even  though  establishing  local
production  faces  considerable  challenges  especially  ensuring  adequate  markets  on the  continent.  There
is an  urgent  need  to develop  effective  communication  messages  for decision  makers  as well as  healthcare
workers  addressing  the  importance  of inﬂuenza  even  in the  face  of the  major  competing  health  burdens
© 201
of  the  continent.
. Introduction
At the time of the ﬁrst Afriﬂu conference which was held in
arrakech, Morocco 1–2 June 2010, Africa was seen as a conti-
ent where relatively little attention has been paid to inﬂuenza and
he least empowered part of the planet for inﬂuenza surveillance
nd control [1]. Signiﬁcant progress has been made in the 2 years
ince then. More and more countries are carrying out surveil-
ance and some 24 African countries now contribute specimens
o WHO, 5 of them contributing about 1000 or more specimens
nnually. The median positivity for ILI is 15.6% and for SARI is 8.9%
eﬂecting a progressively more productive surveillance programme
hroughout the continent [2]. Recent publications, including a com-
lete supplement of the Journal of Infectious Diseases, are now
tarting to throw considerably more light on the regional bur-
en of inﬂuenza and also on regional responses to vaccination
3]. Another African inﬂuenza initiative, that of the African Net-
ork for Inﬂuenza Surveillance and Epidemiology (ANISE), held
ts third annual meeting in February 2012 in Nairobi, Kenya [4].
Abbreviations: DCVMN, developing countries vaccine manufacturers network;
LI, inﬂuenza-like illness; LAIV, live-attenuated inﬂuenza vaccine; SAGE, strategic
dvisory group of experts on immunisation; SARI, severe acute respiratory illness;
IV, trivalent inactivated inﬂuenza vaccine; WHO, World Health Organization.
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This meeting dealt comprehensively with recent progress in the
development of surveillance programmes on the continent.
This, the second of the Afriﬂu conferences, was held immedi-
ately preceding the ﬁrst International African Vaccinology Congress
in Cape Town, 9–11 November 2012. Afriﬂu2 was organised jointly
by the Agence de Médecine Préventive (AMP, www.aamp.org)
and the National Institute for Communicable Diseases (NICD) of
South Africa (www.nicd.ac.za). Over 60 delegates from 15 African
countries and from several non-African countries met  to focus on
inﬂuenza vaccines and vaccination with relevance to the African
continent. The meeting was divided into three streams – ﬁrst,
the burden of inﬂuenza and effectiveness of inﬂuenza vaccines in
Africa; second, deﬁning the risk groups for prioritisation to receive
vaccine; and third, vaccine security, an issue of especial importance
to the African continent.
This paper is a report of the deliberations of the meeting which
sought to answer four fundamental African public health questions
regarding inﬂuenza: (1) How important is inﬂuenza in Africa? (2)
In whom is it of particular importance? (3) How well do vaccine
interventions work on the African continent? (4) How secure is
Africa for supplies of seasonal and pandemic inﬂuenza vaccines
given that there is currently almost no indigenous inﬂuenza vaccine
production on the continent?
Open access under CC BY-NC-SA license.2. Is inﬂuenza of importance in Africa?
Reports from the four subregions of the WHO  African
Region – southern, central, eastern and western – were presented.
icense.
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niformly, inﬂuenza has been commonly associated with respi-
atory illness throughout the continent, involving both the upper
nd lower respiratory tract. The estimated burden of illness in
frica was usually but not always greater than that of developed
ountries. For example in a comparative study of excess mortality
n the elderly (≥65 years) between South Africa and the USA, it was
ound that the relative risk of all-cause deaths in South Africa was
.1 times that of the USA, while pneumonia and inﬂuenza-related
eaths and all-cause respiratory deaths were 3.0 and 3.5 times,
espectively [5]. However rates of hospitalisation from a study
n Kenya were comparable with an equivalent USA study [6,7],
espite overall diverging health seeking behaviour patterns.
.1. Surveillance
The quality of surveillance in Africa has improved dramati-
ally in all subregions since 2006 when less than 5000 specimens
ere processed, mainly in South Africa. In 2010, over 40,000 spec-
mens from all regions were processed. Of some 33,357 specimens
rocessed by 24 African countries in 2012 (up to 2nd November)
1% were positive for inﬂuenza with the medians in 15 of these
ountries for ILI being 15.6% and SARI 8.9% [2]. The percent of
solates collected from patients with mild or severe respiratory dis-
ase that yielded inﬂuenza was similar throughout the continent,
lthough there was a wide range. Major challenges to obtaining
ood surveillance data still remain, particularly in many countries
n the central and western subregions where high-level commit-
ent from government is lacking and, at present, the major portion
f funding for surveillance still comes from outside sources. The
ifﬁculty in obtaining good data is also compromised by variations
n health seeking behaviour seen in different countries. The great
ajority of ILI patients do not seek medical care and very few of
hose who do, get tested for inﬂuenza. There has, nevertheless, been
 signiﬁcant increase in the number of countries in Africa reporting
ata, as well as providing inﬂuenza strains to WHO. Surveillance
s currently most extensive in South Africa with 250 ILI sites while
ARI is investigated in six hospitals representing urban and rural
opulations [8]. In Kenya surveillance for both ILI and SARI has
een undertaken at several sites from the coastal region to inland
rban populations and rural sites in the west of the country [2,6–8].
ameroon has also established 20 ILI sites in nine regions and two
ARI sites in one region [9]. In West Africa, Ghana has surveillance
rogrammes in all of its 10 regions, with 22 ILI and 4 SARI sites [10].
.2. Burden of disease
Relatively good consistency was found between the various
ethods used for burden of disease measurement. Severe disease
nd death in SARI patients was strongly associated with coinfection
ith HIV [11], tuberculosis [12] and Streptococcus pneumoniae [13]
n South Africa. However, the role of coinfection was  not appar-
nt in SARI patients in Malawi where a preliminary analysis found
hat malaria coinfection with HIV and tuberculosis also did not
ppear to be independent risk factors [14]. Similarly in Kenya there
s limited evidence of an increased inﬂuenza risk in HIV patients
nd patients with chronic diseases [15]. In all studies young chil-
ren and infants were at particular risk. For example, in medically
ttended and home-reported ILI in Kenya (2007–2010) the burden
f illness was highest in children less than two years of age and
owest in adults over 50 years of age [8]. In a similar study of SARI
atients in Kenya, inﬂuenza hospitalisations were 1–8/1000 for
hildren <5 years compared to 0.5–0.6/1000 for children ≥5 years
f age [6,7]. Surveillance in the Cameroon showed that 40–70% of
LI cases visiting sentinel sites were in children <5 years of age [9].
hese data underline the importance of immunising young chil-
ren as well as maternal immunisation to protect the very young31 (2013) 3461– 3466
before they can be vaccinated. Efforts to determine disease burden
are underway in Ghana by the Ghana Health Service Public Health
Division following a desktop pilot of a WHO  manual for disease bur-
den estimation in January 2012 [10]. Cases of hospitalizations from
respiratory illness are now reviewed nationally against inﬂuenza
infections detected.
2.3. Seasonality of inﬂuenza
The seasonal distribution of inﬂuenza in Africa differs region-
ally and by country. Thus in the temperate weather of South Africa,
inﬂuenza seasons monitored since 1984 have shown a sharp winter
prevalence with a mean onset in week 23 (second week of June) and
mean peak in week 27 (second week of July); the mean duration of
the season is 11 weeks [16]. In all other African countries that pre-
sented data, with the exception of Zambia, which follows South
Africa’s pattern [17], inﬂuenza appears to occur throughout the
year with various countries on the continent having their own spe-
ciﬁc pattern. In other southern African countries two peaks within
the winter season were observed [2,18,19]. In the more tropical
countries of central, eastern and western Africa inﬂuenza peaked
in the corresponding rainy seasons [9,10].
3. In whom is inﬂuenza of particular importance?
In considering priority groups for seasonal inﬂuenza immunisa-
tion, two  issues need to be taken into account. Firstly, a great deal of
evidence has been accumulated since the WHO  inﬂuenza vaccine
recommendations of 2005 and, because of this, an updated (April
2012) set of recommendations has recently been published [20].
Five priority groups were identiﬁed; the highest being pregnancy,
followed, in no particular order, by four others – health care work-
ers, children less than ﬁve years of age (especially 6–23 months), the
elderly and persons with deﬁned underlying medical conditions.
Secondly, both developed and developing countries need to region-
ally tailor their country-speciﬁc recommendations appropriate to
their prevailing circumstances, basing them on WHO  recommen-
dations – this is particularly applicable to Africa.
3.1. Report of the inﬂuenza working group of the WHO  strategic
advisory group of experts (SAGE) working group on inﬂuenza
vaccines and immunisation
The background to the new WHO  position paper on inﬂuenza
vaccines [20] was  presented. Designating pregnancy as the high-
est priority was  based on multiple sources of evidence that the
risk of inﬂuenza in pregnant women without any other risk fac-
tors is equivalent to that seen in high-risk adults with underlying
medical conditions that predispose them to the complications of
inﬂuenza [21]. If underlying factors are added to pregnancy the
risk becomes even greater. Both excess mortality as well as the
increased risk of hospitalisation have been reported in pregnancy
in Africa [22]. There is also evidence that inﬂuenza vaccination
of pregnant women may  result in increased birth weight of the
infant [23]. Thus, women  in the third trimester without any other
risk factors are over ﬁve times more likely to be hospitalised for
inﬂuenza-related conditions than non-pregnant women  – 10.5
vs. 1.91 per 10,000 women months, respectively [21]. A further
very valuable beneﬁt of vaccination in pregnancy is the protection
afforded to the newborn and young infant less than six months
of age who are not eligible for inﬂuenza vaccination. For example,
a study in Bangladesh demonstrated a 29% reduction in ILI and a
63% reduction in laboratory conﬁrmed inﬂuenza in infants born to
mothers vaccinated in pregnancy [24]. These infants also had sig-
niﬁcantly higher birth weights [25]. Furthermore the safety proﬁle
of inﬂuenza vaccination in pregnancy is excellent.
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Health-care workers were identiﬁed as one of the target groups
ecause of the direct and indirect beneﬁts. Since health care work-
rs are often healthy young adults, they generally respond well
o the vaccine and are at an increased occupational risk of infec-
ion. In addition indirect beneﬁts exist from decreasing the risk of
ransmitting infection to vulnerable patients as well as reducing
bsenteeism in healthcare workers who may  be part of essential
ersonnel in times of crisis.
Young children have the highest incidence of infection with
nﬂuenza, and school-aged children have the highest rates of trans-
ission [26]. Complications are highest in the very young with
ospitalisation rates in infants less than two years of age being
quivalent to those seen in the elderly. Unfortunately, vaccine
fﬁcacy of non-adjuvanted trivalent inactivated inﬂuenza vaccine
TIV) is lower in children less than two years of age and this is also
he case for the elderly who account for the highest rate of hospitali-
ation and up to 90% of all inﬂuenza related deaths in the developed
orld [27].
Although these ﬁve priority groups would also be applica-
le in general to the African setting, comorbidities substantially
ontribute to inﬂuenza burden and mortality on the continent
nd would signiﬁcantly affect regional inﬂuenza vaccine rec-
mmendations. Speciﬁcally, human immunodeﬁciency (HIV) and
uberculosis (TB) co-infections have been shown to play important
oles in aggravating inﬂuenza outcomes in southern Africa [11].
ub-Saharan Africa is home to 2/3 of all persons in the world living
ith HIV (22.5 of 33.3 million), with South Africa having the largest
umber in the world, 5.6 million, and Swaziland the highest preva-
ence in the world, 25.9%. A similar situation exists with TB. South
frica has the third highest burden in the world, 400,000–600,000
ffected and 1% of the population developing TB disease every year
28]. In children, HIV infection increases the risk of deaths asso-
iated with inﬂuenza and inﬂuenza-related pneumonia [29] and
n adults (25–54 years) the excess mortality is increased 150–200
imes that of age matched HIV-negative persons [11]. This is equiv-
lent to what was found in the USA in the pre-HAART era and
s currently 2–4 times that seen in the elderly in South Africa.
ata from South African SARI surveillance sites showed that 45%
f patients hospitalised for acute lower respiratory tract infection
ere HIV positive. In the H1N1 pandemic of 2009 53% of the deaths
n South Africa were in HIV-infected persons and 10% in patients
ith active TB [22].
. How efﬁcacious and effective is inﬂuenza vaccination in
frica?
.1. Vaccine efﬁcacy and effectiveness in the African setting
Few studies of vaccine efﬁcacy and effectiveness have
een carried out in Africa. In South Africa, a randomised
ouble blind placebo-controlled trial of trivalent inactivated
nﬂuenza vaccine efﬁcacy in HIV-infected adults showed it to
e satisfactory at 75.5% (9.2–95.0) [30]. However, another ran-
omised double-blind placebo-controlled trial in HIV-infected
hildren, also in South Africa, in children 6–59 months of
ge, demonstrated absence of trivalent inactivated inﬂuenza
accine efﬁcacy – (from 19.1% [−61.0, 59.9] for laboratory con-
rmed inﬂuenza illness to 22.6% [−36.2, 56.6] for ILI [31]). Mention
as made at this conference of a study in children 6 months to
0 years of age with unknown HIV status in 2 sites in Kenya. The
tudy found that inﬂuenza vaccine was effective in preventing dis-
ase, and this was not unexpected because of the older age of the
ubjects. It should be pointed out that in the South African children’s
tudy the vaccine was not well matched with circulating strains;
evertheless, over and above the mismatch, the immunogenicity31 (2013) 3461– 3466 3463
in this population was intrinsically poor. In elderly South Africans
poor effectiveness of inﬂuenza vaccination – 19.3% – was found in
a small study in a health management setting [32].
5. How can vaccine security be established for Africa?
5.1. Challenges of inﬂuenza vaccination in Africa
Africa lags far behind the rest of the world, not only for inﬂuenza
surveillance, but also for inﬂuenza vaccination. Very few countries
in sub Saharan Africa (including South Africa and Mauritius)
make provision for seasonal inﬂuenza vaccination in their national
immunisation schedule. There is also only one country in sub-
Saharan Africa, South Africa, which has any facility for local ﬁlling
or the potential for future production of inﬂuenza vaccine. These
challenges are compounded by serious logistical obstacles includ-
ing delays in importation and distribution and insufﬁcient buy-in
from healthcare workers and decision-makers especially with the
pressure of competing health priorities.
The vaccine donation initiative for the provision and distribu-
tion of the 2009 pandemic H1N1 vaccines to African countries
illustrated many of these logistical problems. This initiative was
established soon after the advent of the 2009 pandemic by a WHO
– USAID partnership together with the respective governments of
African countries. Some 44 of the 46 WHO  African region mem-
ber states were eligible for donation. In the eastern and southern
African regions 3,391,800 doses were received and 2,048,225 doses
were administered; in the western African region 6,483,300 doses
were received and 5,309,855 administered: and the central African
region received 864,000 doses with 587,164 administered. While
the peak of the pandemic in Africa was  in September of 2009,
the average delay in the procurement process for the region was
261.4 days from signature of the letter of intent to implementation.
Vaccine was  therefore only available well after the pandemic had
declined. Nevertheless much was  learnt from the experience that
will be of value in future planning. Firstly, there was almost unani-
mously a great willingness, responsiveness and commitment to the
initiative, including ﬁnancial, from a number of countries, even to
the extent of urgently adjusting legal requirements and regulations.
Secondly, rumours that circulated globally regarding the efﬁcacy
or safety of the H1N1 vaccine generally had little effect on the
African continent. Thirdly, the exercise also improved the capacity
to respond to future pandemic threats. National task teams have
been established in several countries and an WHO  African Region
Crisis Management Team (CMT) has now been created. What does
need improving for the future is the communication gap at a num-
ber of levels as was  experienced during this exercise.
5.2. Challenges to the development of indigenous vaccine
production in Africa
Sustainable vaccine production is dependent on reliable
demand and reliable supply. The driver for demand is a sustain-
able vaccine procurement policy which itself depends on evidence
of local disease burden, vaccine efﬁcacy and effectiveness and the
priority accorded to inﬂuenza in the face of competing health needs.
In terms of supply, while global production of seasonal vaccine [at
1420 million doses per annum] may  well fall far short of global
needs [33], it is signiﬁcantly in excess of demand and this sur-
plus has grown from 250 million doses in 2007 to 584 million doses
in 2012. What complicates indigenous African vaccine production
even further is that the continent’s market is largely that supplied
from UNICEF and a local manufacturer would face stiff competition
from multinational suppliers to UNICEF – unless some preferential
supply agreement was made. The dilemmas facing a local vaccine
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anufacturer are therefore many, not least of which is the unpre-
ictability of seasonal vaccine demand in a continent still struggling
o afford routine vaccines costing a fraction of inﬂuenza vaccine.
To date technology transfer of inﬂuenza manufacturing capacity
as been exported to 13 countries globally. It may  be appropriate
or new start-up vaccine production in Africa to examine alter-
ate technologies to the classical egg-based TIV. The choice of
hich technology to embark on will depend on cost and the time
t would take for production to come on line. For example, to pro-
uce 20 million doses per year, egg-based live-attenuated inﬂuenza
accine (LAIV) vaccine, which would be the cheapest option at
pproximately US$ 1 million, would take two years to come online.
gg-based TIV would cost US$10 million and take four years to
roduction and TIV produced in an established cell culture line
S$100 million and six years to production.
.3. The South African initiative for indigenous vaccine
roduction in Africa
Despite the major challenges outlined above, the need for
ndigenous vaccine production is well recognised. A reliable and
rompt supply of pandemic vaccine depends on sustained seasonal
accine production. To address these needs, a network of manufac-
urers in a number of Latin American, Asian, African and Middle
astern countries has been established under the banner of the
eveloping Country Vaccine Manufacturers Network (DCVMN –
ww.dcvmn.org). This network consists of a substantial number
f indigenous vaccine producers especially in Asia and Latin Amer-
ca. In Africa, a modest amount of vaccines is produced in Egypt,
unisia, Senegal and South Africa. The African Vaccine Manufac-
urers Initiative [AMVI] has been established with a mission to
reate sustainable vaccine manufacturing capacity on the conti-
ent to meet the needs of its peoples. AMVI’s strategic objectives
re to facilitate partnerships, high-level advocacy, mobilisation of
he required resources, and development of appropriate skills.
In sub-Saharan Africa the only inﬂuenza production facility is at
he Biovac Institute in Cape Town, South Africa, a public–private
artnership between the South African government and private
ndustry. At present, this facility has developed the capacity for
ultiproduct formulation and ﬁlling, including that for inﬂuenza
accine imported in bulk. This facility will be inspected at the end of
012 by the local regulatory authority, the South African Medicines
ontrol Council. A future licence for inﬂuenza vaccine manufacture
s anticipated in 2015.
.4. Inﬂuenza initiatives in Africa from non-governmental
rganisations
PATH (www.path.org) is a non-governmental organisation ded-
cated to improving the health of people throughout the world by
dvancing technologies, strengthening systems and encouraging
ealthy behaviours. Approximately 34% of its activities are ded-
cated to vaccine related projects, included in the latter are four
nﬂuenza vaccine projects in Africa. PATH is involved in the col-
ation and analysis of data from maternal immunisation projects
nd is currently collaborating on a large maternal immunisation
tudy in Soweto, South Africa. Another programme involves the
valuation of LAIV using both the Ann Arbor and the Leningrad
AIV vaccine strains. The former has shown consistently better efﬁ-
acy than inactivated vaccine in children ≤2 years – 46% in a recent
eta-analysis [34]. The technology to manufacture Leningrad LAIV,
hich PATH supports predominantly [35], has now been trans-erred to several developing countries and the safety and immuno-
enicity is currently being evaluated in Bangladesh and India. In
enegal a trial of TIV has been launched and in the future an adju-
anted TIV vaccine will also be tested. Adjuvanted TIV has recently31 (2013) 3461– 3466
been demonstrated to be superior to non-adjuvanted TIV in pre-
venting laboratory conﬁrmed inﬂuenza in children 6 to 72 months
of age [36]. LAIV has been shown to be more effective than TIV
in children – 54.9% fewer cases of culture-conﬁrmed inﬂuenza
than the group receiving TIV [37]. A suggested future inﬂuenza
vaccination programme for children could consist of three
phases–immunisation of pregnant women  to protect young infants
less than six months, followed by TIV with or without an adjuvant
up to 2 years and then LAIV after two years for young children.
6. Conclusion
Inﬂuenza remains an enigmatic virus despite being one of the
ﬁrst human viruses isolated, in 1933, and many of its properties
remain to be elucidated. Predicting antigenic changes and the con-
sequences thereof for seasonal inﬂuenza outbreaks is still imprecise
even in developed countries, as seen by the frequency of mis-
matches of vaccine strains. Anticipating pandemics is even more
perplexing, as demonstrated by the unexpectedness of the 2009
H1N1 pandemic. Measuring the burden of disease is hampered by
a lack of clear clinical endpoints, which similarly bedevils precision
in measuring vaccine responses. Finally, inﬂuenza vaccine is unique
among human vaccines in having changed little since its ﬁrst licen-
sure in 1945 and there is clearly much room for improvement. As an
example, in three of the ﬁve priority groups designated by WHO’s
SAGE for inﬂuenza vaccination, i.e., young children, the elderly and
those with underlying medical conditions, the efﬁcacy of the vac-
cine is lower than in healthy young adults. In addition while a
vaccine needing annual renewal and annual administration may  be
inefﬁcient in a developed world setting, it is potentially unusable
in most African settings. Importantly, public awareness and buy-in
from decision-makers in African countries is still unpredictable.
Inﬂuenza has long been neglected on the African conti-
nent, largely because of huge competing health problems. The
proceedings of this, the second Afriﬂu conference, have shown that
there is an increasing awareness of the need for inﬂuenza surveil-
lance and has also demonstrated the value of vaccine interventions
in the African setting. Surveillance has improved and the burden
of inﬂuenza and inﬂuenza related diseases shown to be high, and
often greater than in the developed world. This suggests that the
health value and cost-effectiveness of vaccine interventions could
be high, if logistic, programmatic, production, dosing, and effec-
tiveness issues can be addressed. In addition to the usual cofactors
seen elsewhere in the world, the epidemiology of inﬂuenza and
the inﬂuenza-associated illness burden in Africa is driven to a large
degree by coinfections. In southern Africa this is especially true with
HIV, TB and S. pneumoniae. Tropical diseases and other possible
cofactors prevalent in African countries still need urgent investiga-
tion.
It is clear that vaccine strategies will need to be speciﬁcally tail-
ored to Africa’s needs. For example, although TIV vaccine appears
to be adequately effective in HIV-positive adults, it may  lack efﬁ-
cacy in infants who are HIV positive – a problem of signiﬁcant
importance in sub Saharan Africa. No data are available on the
effectiveness among HIV exposed children. Innovative strategies
are being developed for the continent’s inﬂuenza problems, such
as maternal immunisation, not only because pregnancy offers the
highest priority but also for the protection of the young infant.
Currently LAIV has not been explored to any extent in Africa but
its demonstrable superiority in young children elsewhere in the
world needs to be examined with respect to Africa. Simultaneously,
use of adjuvanted vaccine for young children in Africa needs to
be further investigated. The ﬁnal, and perhaps most important,
African inﬂuenza barrier to be overcome is that of developing and
implementing a communication initiative. This should be directed
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ot only at political decision-makers, but also at the general pub-
ic, especially healthcare workers who at present do not recognise
nﬂuenza as a major problem when weighed against the enormity
f the competing health problems of Africa.
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ppendix A. Afriﬂu2 conference agenda
AGENDA
Afriﬂu workshop 2012
8 November 2012
Cape Town, South Africa
Inﬂuenza immunisation in Africa
ime Topic Presenter
8:00 08:30 Workshop introduction B Schoub (NICD, SA)
8:30 10:30 Disease burden session A Cohen (CDC, SA), P
Ndumbe (Univ. Buea,
Cameroon)
8:30 08:50 Southern Africa perspective A Cohen
8:50 09:10 Central Africa perspective R Njouom (Centre
Pasteur, Cameroon)
9:10 09:30 Eastern Africa perspective J Mott (CDC, Kenya)
9:30 09:50 Western Africa perspective W Ampofo (NMIMR,
Ghana)
9:50 10:30 General discussion
1:00 12:30 Session on priority groups W Ampofo, C Steffen
(AMP, France)
1:00 11:20 SAGE global perspective J Bresee (CDC, USA)
1:20 11:40 Local perspective C Cohen (NICD, SA)
1:40 12:00 Global NGO perspective J Ortiz (PATH, USA)
2:00 12:30 General discussion
4:00 15:30 Vaccine security session B Schoub, B Gessner
(AMP, France)
4:00 14:20 Vaccine production in Africa P Tippoo (Biovac
Institute, SA)
4:20 14:40 WHO  perspective M Friede (WHO,
Geneva)
4:40 15:00 Lessons learnt from the pandemic P Ndumbe
5:00 15:30 General discussion
5:30 16:00 Wrap up and conclusion B Schoubeferences
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